Aspirin alone vs. aspirin plus fondaparinux before early heart catheterization in NSTEMI
Treatments studied
Part of Heart & circulation clinical trials.
This study tests whether taking aspirin alone works as well as aspirin plus a blood thinner called fondaparinux before a heart procedure in people with a specific type of heart attack (NSTEMI). It aims to find the safest and most effective treatment before an early heart catheterization.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a certain type of heart attack (called non-ST elevation myocardial infarction or NSTEMI).
- You are 18 years or older.
- You are not taking any blood thinner medication before the study starts.
- You do not have active bleeding or a high risk of bleeding.
- Your kidneys are working well enough (eGFR above 20).
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a specific stent (with no polymer coating) plus a single blood thinner plan with aspirin and another P2Y12 medicine is as safe and effective as the standard two-medicine plan after a STEMI heart attack. It may help people avoid longer exposure to stronger blood-thinning if the new approach works as well.
This trial tests whether a lower dose of aspirin is safe and effective for patients who have had a heart attack (STEMI) and received a stent. If you've been taking aspirin and ticagrelor after your procedure, you may be able to join.
This trial tests whether giving a blood thinner (heparin) early, before you get to the hospital for a heart attack procedure, can improve outcomes. It is for people having a specific type of heart attack (STEMI) who will receive a balloon angioplasty within 2 hours.
This study tests whether taking dabigatran (a blood thinner) combined with ticagrelor (a blood clot preventer) is safe and effective for patients with irregular heart rhythm (atrial fibrillation) who recently had a heart attack and received a stent. The goal is to prevent future blood clots while minimizing bleeding risks.
This trial tests whether a half-dose medicine called r-SAK given before a primary PCI heart stent procedure improves outcomes and safety in people with a specific type of heart attack. It may help the heart recover better, but it also checks the risk of side effects like bleeding.
This trial compares two common “blood thinner” combinations to prevent problems after a PCI procedure for complex blocked heart arteries. It may help your care team find which combination works better for people with higher-risk artery patterns.
Hear when a new NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.